Skip to main content
  • Icosapent Ethyl Significantly Reduced Ischemic Events in REDUCE-IT Patients With Prior MI: Post Hoc Analysis

    Icosapent ethyl (IPE) significantly reduced ischemic events in patients with prior myocardial infarction (MI) in the Phase IIIb REDUCE-IT trial, including cardiovascular deaths.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details